Description
A prodrug of the HIV reverse transcriptase and hepatitis B virus polymerase inhibitor, tenofovir; >100-fold greater anti-HIV activity than that of poorly bioavailable tenofovir in a T cell line and primary blood lymphocytes
Formal name: (5-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-2,4,6,8-tetraoxa-5-phosphanonanedioic acid, 1,9-bis(1-methylethyl) ester 5-oxide, (2E)-2-butenedioate
Synonyms: Bis(POC)-PMPA
Molecular weight: 635.5
CAS: 202138-50-9
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals|DNA & RNA Polymerase Inhibitors||Product Type|Biochemicals|Antivirals|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)||Product Type|Biochemicals|Small Molecule Inhibitors|Reverse Transcriptases||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Infectious Disease|Viral Diseases|Hepatitis||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS